Module Abstract

Clinical Considerations and Implications for Optimizing Patient Outcomes in Multiple Myeloma

Abstract

Multiple myeloma is an incurable malignancy of plasma cells that will be diagnosed in an estimated 20,580 people in the United States in 2009. The peak occurrence of the disease is between 50 and 70 years of age, with many patients developing bone lesions and renal impairment as a result of the disease. Although incurable, multiple myeloma is highly responsive to several combinations of therapeutic agents and is, therefore, increasingly considered a chronic and manageable disease. Although treatment innovations have improved outcomes, multiple myeloma is characterized by relapses and remissions; therefore, ultimately, most patients will need multiple therapies during the course of their disease. In this CME-certified learning module, R. Donald Harvey, PharmD, FCCP, BCPS, BCOP, and Joseph D. Tariman, PhC, MN, APRN, BC, OCN, review the important clinical considerations for nurses and pharmacists to optimize outcomes and improve the quality of life for patients with multiple myeloma. Topics include an overview of novel agents in the treatment of multiple myeloma, with particular focus on management of adverse events.